艾滋病的分子病毒学和免疫学、基因治疗及抗病毒药物

1、国家自然科学基金重点项目“HIV膜融合机制及强效抑制剂作用机制的系统研究”（82230076）

2、国家自然科学基金重点项目“HIV感染膜融合的动力学及分子机制研究”（81630061）

3、国家自然科学基金面上项目“新型HIV膜融合抑制剂的作用机制和优化”（81473255）

4、国家自然科学基金面上项目 “HIV融合蛋白M-T钩子的结构与功能”（81271830）

5、国家自然科学基金面上项目 “HIV-1融合蛋白核心结构鉴定及新型抑制剂设计”（30870123）

6、国家杰出青年基金项目“医学病毒学”（81025009）

7、十三五国家科技重大专项“基于强效HIV进入抑制剂的暴露前预防策略研究”(2018ZX10301103)

8.十二五国家科技重大专项“基于广谱中和抗体的艾滋病功能性治愈方法究”(2014ZX10001001-001)

9.十一五国家科技重大专项“病原体宿主细胞相互作用药物靶标研究”（2009ZX10004-303）

10.国家重点研发计划“I型包膜病毒侵入机制”（2010CB530102）

1、Yanni Gong, Yuxian He. Cell membrane anchoring strategies for HIV gene therapy. Cell Mol Immunol, 2023,20(6):683-685

2、Jing Xue, Huihui Chong, Yuanmei Zhu, Jingjing Zhang, Ling Tong, Jiahan Lu, Ting Chen, Zhe Cong, Qiang Wei, Yuxian He. Efficient treatment and pre-exposure prophylaxis in rhesus macaques by an HIV fusion-inhibitory lipopeptide. Cell, 2022, 185(1): 131-144

3、Yue Chen, Hongliang Jin, Xiaoran Tang, Li Li, Xiuzhu Geng, Yuanmei Zhu, Huihui Chong, Yuxian He. Cell membrane-anchored anti-HIV single-chain antibodies and bifunctional inhibitors targ eting the gp41 fusion protein: new strategies for HIV gene therapy. Emerg Microbes Infect, 2022, 11(1): 30-49

4、Hongliang Jin, Xiaoran Tang, Li Li, Yue Chen, Yuanmei Zhu, Huihui Chong, Yuxian He. Generation of HIV-resistant cells with a single-domain antibody: implications for HIV-1 gene therapy. Cell Mol Immunol, 2021, 18(3): 660-674

5、Yuanmei Zhu, Danwei Yu, Yue Hu, Tong Wu, Huihui Chong, Yuxian He. SARS-CoV-2 derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses. Signal Transduct Targeted Ther, 2021; 6:294

6、Danwei Yu, Yuanmei Zhu, Yan H, Tong Wu, Huihui Chong, Yuxian He. Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus. Emerg Microbes Infect. 2021; 10(1):810-821

7、Yuanmei Zhu, Danwei Yu, Yang Han, Hongxia Yan, Huihui Chong, Lili Ren, Jianwei Wang, Taisheng Li, Yuxian He. Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recover ed SARS patients and immunized animals. Sci Adv, 2020, 6(45): eabc9999

8、Danwei Yu,Jing Xue, Huamian Wei, Zhe Cong, Ting Chen, Yumei Zhu, Huihui Chong, Qiang Wei, Chuan Qin,Yuxian He. Therapeutic efficacy and resistance selection of a lipopeptide fusion inhibitor in simian immunodeficiency virus -infected rhesus macaques. J Virol. 2020;94(15): e00384-20

9、Yuanmei Zhu, Xiaohui Ding, Danwei Yu, Huihui Chong, Yuxian He. The Tryptophan-Rich Motif of HIV-1 Gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of Gp41 and Its Inhibitors. J Virol. 2020; 94(1): e01358-19

10、Huihui Chong, Jing Xue, Yuanmei Zhu, Zhe Cong, Ting Chen, Qiang Wei, Chuan Qin, Yuxian He. Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppress ion in rhesus macaques. PLoS Pathog, 2019, 15(2): e1007552

1、国家1类抗HIV新药“利普韦肽”进入II期临床试验

2、国家1类抗HIV新药“注射用LP-98”进入I期临床试验

3、国家1类抗SARS-CoV-2新药YKYY017进入II/III期临床试验

4、广谱抗病毒药物IPBZS01实现成果转化并开展Pre-IND研究